Sexual, Gender Minorities With Chronic Skin Diseases More Likely to Face Barriers to Care
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 3, 2023 -- Sexual and gender-minority (SGM) patients with chronic inflammatory skin diseases (CISDs) are more likely to experience cost and noncost barriers to care, according to a study published online Sept. 27 in JAMA Dermatology.
Michael R. Nock, from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted a cross-sectional study of health care access and utilization survey data to compare the prevalence of cost and noncost barriers to care among SGM and non-SGM adult patients with CISDs. Data were included for 19,743 patients with CISDs: 1,877 SGM patients and 17,866 non-SGM patients.
The researchers found that SGM patients with CISDs were significantly more likely to delay specialist care, mental health care, and filling a prescription because of cost compared with non-SGM patients (adjusted odds ratios, 1.23, 1.62, and 1.30, respectively). Compared with non-SGM patients, SGM patients with CISDs were significantly more likely to delay care due to transportation issues (adjusted odds ratio, 1.49) and not having a health care practitioner who shares the same background with regard to race and ethnicity, religion, native language, sexual orientation, and gender identity (adjusted odds ratio, 1.39). SGM patients with CISDs were also more likely to report not always being treated with respect by their health care practitioners compared with non-SGM patients (adjusted odds ratio, 1.47).
"Dermatologists and other health care practitioners caring for SGM patients with CISDs have an important role in helping to address these barriers and larger systemic issues for SGM patients at both the patient and system levels," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.